...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of rheumatology >The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis
【24h】

The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

机译：静脉免疫球蛋白制剂在系统性硬化症治疗中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in scleroderma is progressive development of fibrous tissue and obliteration of the microvasculature. Currently, there are no medical products for the treatment of scleroderma that provide both sufficient immunosuppression and low-risk side safety profile with negligible side effects. There are a large number of experimental data showing that intravenous immunoglobulin (IVIG) has multiple clinical and morphological effects. On the other hand, some authors report good effect of intravenous immune globulins in patients with scleroderma. The less frequent side effects of IVIG in doses below or equal to 2 g/kg/month divided in 5 consecutive days make IVIG a promising treatment of choice in scleroderma.
机译：硬皮病是与严重残疾相关的进行性自身免疫疾病。硬皮病的主要潜在病理过程是纤维组织的逐步发展和微脉管系统的闭塞。当前，没有用于治疗硬皮病的医疗产品提供足够的免疫抑制和低风险的副作用，而副作用可忽略不计。有大量实验数据表明，静脉免疫球蛋白（IVIG）具有多种临床和形态学作用。另一方面，一些作者报告静脉注射免疫球蛋白在硬皮病患者中效果良好。 IVIG剂量低于或等于2μg/ kg / month的较不频繁的副作用（连续5天分配）使IVIG成为硬皮病的有希望的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号